HHS commits $25M to ibogaine and other psychotropic drugs

HHS Invests in Psychedelic Research

The U.S. Department of Health and Human Services (HHS) has announced a significant investment in ibogaine and other psychotropic drugs, aiming to address serious mental illnesses such as post-traumatic stress disorder (PTSD). Announced on Thursday, the initiative includes up to $4.9 million through the Advanced Research Projects Agency for Health (ARPA-H) to develop these treatments, particularly for veterans, according to the HHS announcement.

Funding Details and Future Plans

This initial funding will be allocated over five years, with further awards planned to explore ibogaine's potential for treating substance use disorders. These awards will support regulatory and manufacturing efforts necessary for future clinical trials. "Veterans kept their promise to this country. We must keep ours," Health Secretary Robert F. Kennedy Jr. stated, emphasizing the need for scientific investigation into ibogaine's effects.

Broader Research Network

In addition to ibogaine, the National Institute of Mental Health is offering a $20 million funding opportunity to establish a research network focused on rapid-acting psychotropic drugs. This includes ketamine, esketamine, and psilocybin, among others. Johnson & Johnson's esketamine nasal spray, Spravato, approved in 2019, exemplifies the potential of such treatments.

Clinical Trials and Safety Concerns

DemeRx is set to launch the first U.S. clinical trial of an ibogaine-derived drug, marking a pivotal moment for the compound, which has been controversial due to safety concerns. Despite its therapeutic promise, ibogaine is associated with neurotoxic and cardiotoxic effects, with 33 deaths recorded in published literature as of 2022. The FDA recently cleared DemeRx's noribogaine candidate DMX-1001 for first-in-human testing, with a Phase 2 trial in alcohol use disorder planned for next year.

Why It Matters

This investment underscores the growing interest in psychedelic compounds as potential treatments for mental health disorders, particularly for veterans. The focus on ibogaine reflects a broader trend in exploring unconventional therapies that may offer new hope for individuals with treatment-resistant conditions. Understanding ibogaine's "matrix pharmacology" could unlock new therapeutic pathways while addressing its associated risks.

The HHS initiative follows recent FDA submissions for psilocybin therapeutics, highlighting a shift towards integrating psychedelic research into mainstream medicine.